

Prostate Cancer PSP completed in 2010																
Indicative Uncertainty		Why is there uncertainty?	What is person's age?	Which types of treatments?	Which types of treatments? 2	Which types of treatments? 3	Which types of treatments? 4	Which types of treatments? 5	Which types of treatments? 6	Which types of treatments? 7	Source	References to reliable up-to-date systematic reviews	Systematic reviews in preparation	Systematic reviews that need updating or extending	Ongoing controlled trials	Which outcomes?
Are there any dietary measures that can prevent prostate cancer or slow its progression?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diet							Prostate Cancer – A JLA Priority Setting Partnership			Hasen F, Cantwell MM, O'Sullivan JM, Murray LJ. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. <i>Prostate Cancer and Prostatic Diseases</i> . 2008;12(4):253&#226;332 PMID 19901932		Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient; and cost
Are there any non-intrusive diagnostic tests that will identify aggressive prostate cancers whilst not identifying harmless cancers?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Adult	Diagnostic							Prostate Cancer – A JLA Priority Setting Partnership			lic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2		A non-intrusive diagnostic tests that will identify aggressive prostate cancers whilst not identifying harmless cancers
Do variations in GP awareness of prostate cancer affect outcomes?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer – A JLA Priority Setting Partnership					Knowledge of prostate cancer in general practice; change in outcomes for patients
Does active surveillance work for treatment of prostate cancer?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Diagnostic							Prostate Cancer – A JLA Priority Setting Partnership			Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace Kazer M. Radical prostatectomy versus watchful waiting for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2010, Issue 11. Art. No.: CD006590. DOI: 10.1002/14651858.CD006590.pub2		Disease progression; adverse effects; cost; acceptability
Does serial PSA measurement in patients with prostate cancer accurately monitor disease progression?	Uncertainties identified from clinicians' questions	Relevant reliable up-to-date systematic reviews do not address continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer – A JLA Priority Setting Partnership			lic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2		Monitoring of disease progression
How can over-treatment for prostate cancer be prevented by identifying and excluding the treatment of harmless tumours?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer – A JLA Priority Setting Partnership	Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace Kazer M. Radical prostatectomy versus watchful waiting for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2010, Issue 11. Art. No.: CD006590. DOI: 10.1002/14651858.CD006590.pub2 lic. D., O'Connor, D., Green, S. and Wilt, T. J. (2011). Screening for prostate cancer: an updated Cochrane systematic review. <i>BJU International</i> , 107: 882–891. doi: 10.1111/j.1464-410X.2010.10032.x Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity&#228;modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> 2010;14(47):1&#226;108	Boustead G, Edwards S J. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta&#228;analysis of randomized controlled trials. <i>British Journal of Urology International</i> . 2007;99(5):1383&#226;1389. De Coni P, Atallah AN, Arruda HO, Soares B, El Dib R, Wilt T. Intermittent versus continuous androgen suppression for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2007, Issue 4. Art. No.: CD005009. DOI: 10.1002/14651858.CD005009.pub2		Over-treatment of harmless prostate cancer; identification of types of prostate cancer	
Is there a genetic marker for prostate cancer that would be both more sensitive and more specific than PSA serum level?	Uncertainties identified from clinicians' questions	Relevant reliable up-to-date systematic reviews do not address continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer – A JLA Priority Setting Partnership			lic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2		Sensitivity; specificity; adverse effects; cost; acceptability to patients
Is there a vaccine that can prevent prostate cancer?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Any age	Vaccines and biologicals							Prostate Cancer – A JLA Priority Setting Partnership			BlueCross BlueShield Association. Special report: vaccines for the treatment of prostate cancer. Chicago IL: Blue Cross Blue Shield Association (BCBS). 2009.		Incidence of prostate cancer; adverse effects; acceptability; cost
What can be done to delay or prevent the onset of hormone independent prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diet	Drug	Physical therapies	Vaccines and biologicals				Prostate Cancer – A JLA Priority Setting Partnership			Wilt T.J, Nair B, MacDonald R, Rutle I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. <i>Cochrane Database of Systematic Reviews</i> 2001, Issue 4. Art. No.: CD003506. DOI: 10.1002/14651858.CD003506		Change in onset of hormone independent prostate cancer
What is the effectiveness of new treatments for prostate cancer such as High Intensity Focused Ultrasound (HIFU) and Cryotherapy?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Drug	Devices	Surgery					Prostate Cancer – A JLA Priority Setting Partnership			Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high&#228;intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. <i>European Urology</i> ;2010;58(6):803&#226;815		Efficacy; effectiveness; adverse effects
Are complementary and alternative (CAM) therapies safe for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Complementary therapies							Prostate Cancer, A JLA Priority Setting Partnership					Safety
Are complementary and alternative therapies useful following treatment for men living for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Complementary therapies							Prostate Cancer, A JLA Priority Setting Partnership			Smith J E, Richardson J, Hoffman C, Pilkington K. Mindfulness-based stress reduction as supportive therapy in cancer care: systematic review. <i>Journal of Advanced Nursing</i> 2006;75(3):7315-327	Living well with prostate cancer: A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient; and cost

Are genetic factors a good tool to predict prognosis of prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership			Noorani H Z, McGahan L. Predictive genetic testing for breast and prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCHTA)?1999:785	Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives NCT01013129	Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom NCT00758173 Gene-Environment Interaction in Prostate Cancer NCT00041847	Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Are PET scans accurate for staging of prostate cancer?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership			Dussault F, Van H Nguyen, Rachel F. Positron emission tomography in Quebec. Montreal, PQ, Canada: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS). AETMIS; 01-3 RE. ?2002			Diagnosis
Are there age related clinical indicators that limit the use of radiotherapy and chemo therapy for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Drug	Radiotherapy						Prostate Cancer: A JLA Priority Setting Partnership			http://www.iness.qc.ca/fileadmin/doc/AETMIS/...2001_03_en.pdf			Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Are there alternative treatments to hormone therapy that have less impact on Quality of Life for men with prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Vaccines and biologicals	Surgery	Prostate Cancer: A JLA Priority Setting Partnership						Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Are there any effective drug treatments for prostate cancer that would replace the need for surgery and/or radiotherapy?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership						Avoidance of surgical intervention; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Are there any effective treatments for a prostate cancer patient with urinary incontinence?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Environmental	Diet	Drug	Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership	Campbell SE, Glazener CMA, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD001843. DOI: 10.1002/14651858.CD001843.pub4.		Improving continence and quality of life in prostate cancer patients (StayDry) http://clinicaltrials.gov/show/NCT01365642		Urinary incontinence-Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Are there any interventions to help prostate cancer patients who develop psychological effects (such as anxiety, depression) over the course of active surveillance?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Environmental	Psychological therapy	Drug	Diet	Physical therapies		Prostate Cancer: A JLA Priority Setting Partnership	Chambers SK, Pennock C, Lepore SJ. A systematic review of psychosocial interventions for men with prostate cancer and their partners. Patient Education and Counseling 2011; 85(2): e75-e88		Living Well with Prostate Cancer: A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer ACTRN12612000306819		Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Are there any more reliable means of testing for prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Ruiz-Aragon J, Marquez-Pelaez S. Evaluacion del test PCA3 para el diagnostico de cancer de prostata: revision sistematica y metanalisis. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis] Actas Urológicas Espanolas 2010; 34(4): 346-355	Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1(2): 1-95 Eicher K, Wiley J, Hampel S, Myers L, Kleijnen J. Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review. Centre for Reviews and Dissemination (CRD). CRD Report 29. 2005. Umbehr M, Bachmann LM, Kuharawicz J, Steurer J. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. European Urology 2009; 55(3): 575-591	BiopSave: validation of a novel blood test for the diagnosis of prostate cancer/BiopSave ISRCTN52361606	Diagnosis		
Are there any non-invasive diagnostic tests that will identify aggressive prostate cancer patients whilst not identifying harmless cancers? (Tigers and Pussycats)	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership						Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Are there any treatments for prostate cancer that have minimal effect on urinary continence?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Drug	Diet	Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership						Urinary incontinence-Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost

Are there indicators of the correct time for starting individual treatments for prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Drug	Radiotherapy	Surgery					Prostate Cancer: A JLA Priority Setting Partnership					Timing: symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Are there ways (complementary or conventional) to alleviate the side effects of hormone therapy taken for prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership					Adverse effects
Are variations in practice by non-specialist clinicians detrimental to outcomes for treatment of prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training	Service delivery						Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Can exercise therapy improve outcomes for prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise							Prostate Cancer: A JLA Priority Setting Partnership	Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD006145. DOI: 10.1002/14651858.CD006145.pub3 Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. Journal of Pain Symptom Management 2012; 43(1):96-110. <a href="http://www.sciencedirect.com/science/article/pii/S0885392411002077">http://www.sciencedirect.com/science/article/pii/S0885392411002077</a>	Exercise intervention for prostate cancer patients from the RADAR study <a href="http://www.anzctr.org.au/ACTRN12609000729224.aspx">http://www.anzctr.org.au/ACTRN12609000729224.aspx</a>	Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost		
Can genetic testing for prostate cancer reduce my risk of being wrongly diagnosed, and over- or under-treated?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership		Noorani H Z, McGahan L. Predictive genetic testing for breast and prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Évaluation des Technologies de la Santé (CCOHTA) 1999:786		Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Can I rely on the PSA test alone to monitor prostate cancer recurrence after radical treatment?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Chou R, Crosswell JM, Dana T. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Annals of Internal Medicine 2011; 155(11): 762-771		Recurrence		
Can needle biopsy of the prostate cause cancer to spread?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Surgery							Prostate Cancer: A JLA Priority Setting Partnership	Ilic D, O'Connor D, Green S, Witt TJ. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2		Adverse effects		
Can prostate cancer spread after transurethral resection of the prostate (TURP) procedure?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic	Surgery						Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Can the prostatectomy procedure cause prostate cancer cells to spread?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic	Surgery						Prostate Cancer: A JLA Priority Setting Partnership				Disease spread	
Complementary therapies for prostate cancer: is there any evidence of their efficacy/effectiveness?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Complementary therapies							Prostate Cancer: A JLA Priority Setting Partnership		Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. British Journal of Cancer 2006; 94(3):7372-90	Genistein in treating patients with prostate cancer <a href="http://clinicaltrials.gov/show/NCT01126879">http://clinicaltrials.gov/show/NCT01126879</a>	Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Could electronic/computerised equipment help standardise the interpretation of diagnostic tests such as the Digital Rectal Exam for men with prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Diagnosis	
Could the use of standard systems (e.g. nomograms) to assess prostate cancer risk and response to treatment improve outcomes?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Diagnosis	
Do delays in reporting prostate symptoms to GPs affect disease outcomes?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Education and training	Service delivery						Prostate Cancer: A JLA Priority Setting Partnership	Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, Wallace Kazer M. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD006590. DOI: 10.1002/14651858.CD006590.pub2. Witt TJ, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD003506. DOI: 10.1002/14651858.CD003506.	A Swedish trial comparing two different follow-up schedules for patients with low-risk prostate cancer on active surveillance with selective, delayed treatment (SAMS-FU) ISRCTN64891728	Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost		
Do medications that target genes have better effects on prostate cancer treatment?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost	

Do statins have a beneficial effect in preventing prostate cancer?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership	Bansal D, Undela K, D'Cruz S, Schifano F. Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. 2012. PLoS ONE. <a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046691">http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046691</a>		Bonovas S, Filicucci K, Sitaras NM. Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. International Journal of Cancer 2008; 123(4): 899-904. Browning D R, Martin R M. Statins and risk of cancer: a systematic review and meta-analysis. International Journal of Cancer 2007; 120(4): 833-843	Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Do variations in GP awareness of prostate cancer affect outcomes?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does a combination treatment of hormone therapy and chemotherapy for prostate cancer improve the disease outcome?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does a digital rectal exam alone or in combination with other tests improve diagnosis of prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Bic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2.	Selley S, Donovan J, Faulkner A, Coast J, Gillart D. Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment 1997; 1(2): 1-96. Hoogendam A, Buntinx F, de Vet H C. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Family Practice 1999; 16(6): 621-626.	STHLM3 - Prostate cancer diagnostic trial?STHLM3 ISRCTN8445406	Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does access to the latest diagnostic equipment improve outcomes for prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does access to the latest treatment equipment improve outcomes for prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Surgery	Vaccines and biologicals	Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does active surveillance work for treatment of prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership	Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S. Active surveillance in men with localized prostate cancer: a systematic review. Annals of Internal Medicine. 2012; 156(8): 582-7590	Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study NCT01376661	Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Does assessing risk factors affect my risk of being wrongly diagnosed with prostate cancer and over- or under-treated?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic	Service delivery						Prostate Cancer: A JLA Priority Setting Partnership	Prostate Px (Aureon Laboratories Inc.) for prediction of recurrence of prostate cancer Lansdale: HAYES, Inc. 2010 <a href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?lInkFrom=OAI&amp;ID=32010000979">http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?lInkFrom=OAI&amp;ID=32010000979</a>		Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Does complementary therapy help with quality of life in patients on active surveillance for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Complementary therapies							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does consuming alcohol affect my risk of developing prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diet							Prostate Cancer: A JLA Priority Setting Partnership				Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does early detection of prostate cancer give more effective treatment options?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does EBRT (external beam radiotherapy) for prostate cancer cause bone necrosis?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Radiotherapy							Prostate Cancer: A JLA Priority Setting Partnership				Bone necrosis
Does excessive coffee drinking affect prostate cancer risk?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diet							Prostate Cancer: A JLA Priority Setting Partnership				Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost

Does having had a vasectomy increase my risk of prostate cancer?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Surgery							Prostate Cancer: A JLA Priority Setting Partnership			Tang LF, Jiang H, Shang XJ, Zhao LM, Bai Q, Hong K, Liu DF, Liu JM, Yuan RP, Chen Q, Ma LL. Vasectomy not associated with prostate cancer: a meta-analysis. Zhonghua Nan Ke Xue Za Zhi. National Journal of Andrology 2009; 15(6): 545-550		Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does my risk of prostate cancer depend on how sexually active I am, or have been?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental							Prostate Cancer: A JLA Priority Setting Partnership					Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does patient information on drugs used to treat prostate cancer have any effect on outcomes?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does serial PSA measurement in patients with prostate cancer accurately monitor disease progression?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does the lack of knowledge of the range of treatments for different types of prostate cancer affect outcomes?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does the provision of specialists/cancer support groups or specialist health care workers who provide more information on prostate cancer treatment improve outcomes?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership			Campbell H S, Phaneuf M R, Deane K. Cancer peer support programs: do they work? Patient Education and Counseling?2004;75(1):73-15		Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does the way information is provided affect quality of diagnosis, choice of appropriate treatment or outcome for patients with prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership			Evaluating patient preferences for the treatment of localized prostate cancer - a discrete choice experiment <a href="http://clinicaltrials.gov/show/NCT01177865">http://clinicaltrials.gov/show/NCT01177865</a>		Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Does Vitamin D production, following exposure to sunlight provide protection against prostate cancer?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership			Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 2007; 167(16): 1730-7	Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer w/ D & Pca NCT00953229	Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Has the adoption of target times for prostate cancer referrals and treatment had a beneficial effect on outcomes?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Service delivery							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
How accurate is the Gleason system as a mechanism for grading prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
How can I check and detect early signs of prostate cancer myself?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
How can over-treatment for prostate cancer be prevented by identifying and excluding the treatment of harmless tumours? (Tigers & Pusycyas)	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost

How do we prevent radical prostatectomy causing urinary incontinence?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Surgery							Prostate Cancer: A JLA Priority Setting Partnership	Campbell SE, Glazener CMA, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. <i>Cochrane Database of Systematic Reviews</i> 2012, Issue 1, Art. No.: CD001843. DOI: 10.1002/14651858.CD001843.pub4. The value of the various approaches to conservative management of postprostatectomy incontinence after radical prostatectomy remains uncertain.		Wheelaan J, Scott N A, Cartmill R, Marshall V, Morton R P, Nacey J, Maddern G J. Minimally invasive non-laser thermal techniques for prostatectomy: a systematic review. <i>BJU International</i> 2000;786(9):797-988 URL: <a href="http://www.blackwell-synergy.com/doi/full/10.1046/j.1464-410x.2000.00976">http://www.blackwell-synergy.com/doi/full/10.1046/j.1464-410x.2000.00976</a>	Urinary incontinence
If I avoid certain chemicals in the work place/environment, will I reduce my risk of developing prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental							Prostate Cancer: A JLA Priority Setting Partnership		Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives NCT01013129 Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom NCT00758173 Gene-Environment Interaction in Prostate Cancer NCT00041847	Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Intervention for prostate cancer prevention approaches	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership		Prostate Cancer Prevention Trial With Quercetin and Genistein QUERCEN NCT015383160 Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation NCT01265953 High Risk Prostate Cancer Prevention Study NCT01174953 Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia NCT00780754 Lycopene in Preventing Prostate Cancer in Healthy Participants NCT00322114	Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is a combination of LH-RH analogue and oestrogen a valid treatment for advanced prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership			Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is a Digital Rectal Examination safe if performed shortly after biopsy for prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Physical therapies							Prostate Cancer: A JLA Priority Setting Partnership	Illic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. <i>Cochrane Database of Systematic Reviews</i> 2006, Issue 3, Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2.		Adverse effects	
Is adjuvant chemotherapy effective in patients with aggressive prostate cancer?	Uncertainties identified from research recommendations	Existing relevant systematic reviews are not up-to-date	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership		Serpa Neto A, Tobias-Machado M, Kaliks R, Wroclawski ML, Pompeo ACL, Del Giglio A. Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 Randomized Clinical Trials. <i>Clinical Genitourinary Cancer</i> 2011, Volume 9(2) 115-123 URL: <a href="http://www.sciencedirect.com/science/article/pii/S1559767311000103">http://www.sciencedirect.com/science/article/pii/S1559767311000103</a> .	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is external beam radiotherapy effective for treating prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Radiotherapy							Prostate Cancer: A JLA Priority Setting Partnership	Bannuru RR, Dvorak T, Obadan N, Yu WW, Patel K, Chung M, Ip S. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. <i>Annals of Internal Medicine</i> 2011 155(3) 171-178. URL: <a href="http://annals.org/article.aspx?articleid=479626">http://annals.org/article.aspx?articleid=479626</a>	Wilt T J, Shamliyan T, Taylor B, MacDonald R, Tacklind J, Rutks I, Koeneman K, Cho C S, Kane R L. Comparative effectiveness of therapies for clinically localized prostate cancer. <i>Rockville, MD, USA: Agency for Healthcare Research and Quality. Comparative Effectiveness Review</i> ; 13. 2008	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is MRI suitable to use for monitoring prostate cancer as part of an Active Surveillance programme?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic	Devices						Prostate Cancer: A JLA Priority Setting Partnership			Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is there a curative treatment for prostate cancer that does not destroy a man's fertility and sex life?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Environmental	Diet	Drug	Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership	Miles C, Candy B, Jones L, Williams R, Tookman A, King M. Interventions for sexual dysfunction following treatments for cancer. <i>Cochrane Database of Systematic Reviews</i> 2007, Issue 4, Art. No.: CD005540. DOI: 10.1002/14651858.CD005540.pub2.		Fertility; intercourse; quality of life	

Is there a genetic marker for prostate cancer that would be both more sensitive and more specific than PSA serum level?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Ruiz-Aragon J, Marquez-Pelaez S. Evaluacion del test PCA3 para el diagnostico de cancer de prostata: revision sistematica y metanalisis. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis] Actas Urológicas Españolas 2010; 34(4): 346-355		Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technology Assessment 2009; 13(5): 1-242 HTA-Noorani H Z, McGahan L. Predictive genetic testing for breast and prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 1999; 85	Prostate Cancer Antigen 3 (PCA-3) Gene Project NCT01177436 A clinical study to access the change in the score of two biomarkers in patients who are beginning treatment with androgen deprivation therapy (Triptorelin 22.5mg) that have advanced prostate cancer Prostate cancer antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) score changes during initiation of androgen deprivation therapy (ADT) with triptorelin 22.5mg in patients with advanced prostate cancer (Pca): a phase III, single arm multicentre study. - TRIPTOCARE <a href="http://apps.who.int/trialssearch/trial.aspx?trialid=EUCTR2009-012786-88-NL">http://apps.who.int/trialssearch/trial.aspx?trialid=EUCTR2009-012786-88-NL</a>	Symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Is there a monitoring regime that will give earlier indication of the requirement /need for follow up further treatment for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Service delivery							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Is there a more reliable way of distinguishing benign prostate diseases from prostate cancer to improve outcomes for those diagnosed with prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership			Can 3-Testa Magnetic Resonance imaging of the prostate be useful in making the decision to perform prostate biopsy in men with a high or concerning prostate specific antigen (PSA) ? <a href="http://www.anzctr.org.au/ACTRN12612001137886.aspx">Http://www.anzctr.org.au/ACTRN12612001137886.aspx</a>	Diagnosis	
Is there a treatment for prostate cancer that will be effective to the end of a man's normal life span?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Vaccines and biologicals	Surgery	Prostate Cancer: A JLA Priority Setting Partnership			Wilt T J, Shamlivan T, Taylor B, MacDonald R, Tacklind J, Rutks I, Koeneman K, Cho C S, Kline R L. Comparative effectiveness of therapies for clinically localized prostate cancer. Rockville, MD, USA: Agency for Healthcare Research and Quality; Comparative Effectiveness Review; 13. 2008	Symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is there a vaccine that can prevent prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Vaccines and biologicals							Prostate Cancer: A JLA Priority Setting Partnership	Provenge (Dendreon Corp.) vaccine for treatment of prostate cancer Lansdale: HAYES, Inc., Healthcare Technology Brief Publication, 2011 Guzman Herrador B, Llanos Mendez A. Efectividad y seguridad de la inmunoterapia activa frente a la telomerasa en el cancer de organo solido. [Effectiveness and safety of active immunotherapy against telomerase in solid-organ cancer] Sevilla: Andalusian Agency for Health Technology Assessment (AETSA) AETSA 2009/2-3. 2011 Canadian Coordinating Office for Health Technology Assessment. Vaccines for metastatic hormone-refractory prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005:74	Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer NCT01446731 A randomized clinical trial of personalized peptide vaccination with oral low-dose metronomic cyclophosphamide for metastatic castration-resistant prostate cancer (CRPC) <a href="http://apps.who.int/trialssearch/trial.aspx?trialid=JPRN-UMIN000003323">http://apps.who.int/trialssearch/trial.aspx?trialid=JPRN-UMIN000003323</a> Phase II clinical trial of personalized peptide vaccination for Prostate cancer patients <a href="http://apps.who.int/trialssearch/trial.aspx?trialid=JPRN-UMIN000003028">http://apps.who.int/trialssearch/trial.aspx?trialid=JPRN-UMIN000003028</a> A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 MUC1 NCT00662007	Incidence of prostate cancer; symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost		
Is there a way of preventing or delaying the spread of prostate cancer outside prostate gland?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Environmental	Drug	Diet	Physical therapies	Vaccines and biologicals	Surgery	Prostate Cancer: A JLA Priority Setting Partnership	Hegarty Josephine, Beirne Paul V, Walsh Ella, Comber Harry, Fitzgerald Tony, Wallace Kazer Meredith. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database of Systematic Reviews: Reviews 2010; Issue 11			Symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is there an increase in the number of younger men developing aggressive prostate cancer? If so, does it affect treatment outcomes?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Incidence of prostate cancer; symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Is there any evidence that individualising treatment for prostate cancer has benefits?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Environmental	Exercise	Drug	Diet	Physical therapies	Surgery	Vaccines and biologicals	Prostate Cancer: A JLA Priority Setting Partnership	Cuppone F, Bris E, Giannarelli D. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 2010; 10:675			Symptom control: symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	

Is there evidence that men with prostate cancer and low PSA serum levels at diagnosis have worse outcomes?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic								Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Is there likely to be a new test for prostate cancer that will improve outcomes for those diagnosed?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic								Prostate Cancer: A JLA Priority Setting Partnership	Predictive Value of Prostate-specific Antigen Isotom 1295a and its Derivates in the Diagnosis of Prostate Cancer NCT01672411			Diagnosis
Patient education of prostate cancer to improve outcomes	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training								Prostate Cancer: A JLA Priority Setting Partnership	A randomised controlled trial evaluating the efficacy of an online decision aid for unaffected men with a family history of prostate cancer ACTRN12611000850976			Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Should men who had prostatitis or epididymitis be screened for prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Diagnostic								Prostate Cancer: A JLA Priority Setting Partnership	Development of early diagnostic kit for prostate cancer ChICTR-DNRC-08000178			Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Should patients monitor their PSA history?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic								Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What are the best after-care measures for men who have had radical treatment for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Diet	Drug	Physical therapies	Psychological therapy			Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What are the best treatments for men with prostate cancer over the age of 70?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Diet	Drug	Physical therapies	Vaccines and biologicals	Surgery		Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What are the effective treatments for the side effects of hormone therapy taken for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Vaccines and biologicals			Prostate Cancer: A JLA Priority Setting Partnership				Control of adverse effects
What are the side effects on the bowel of radiotherapy for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Radiotherapy								Prostate Cancer: A JLA Priority Setting Partnership				Control of adverse effects
What can be done to delay or prevent the onset of hormone independent prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Drug								Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What can I avoid to prevent the growth of a tumour in the prostate?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Vaccines and biologicals			Prostate Cancer: A JLA Priority Setting Partnership				Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What evidence is there that a prostate cancer awareness programme would improve outcomes?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Education and training								Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the appropriate timing for undertaking radiotherapy in relation to prostate surgery?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Adult	Radiotherapy								Prostate Cancer: A JLA Priority Setting Partnership	Morgan S C, Waldron T, Eapen L, Mayhew L A, Winquist E, Lukka H. Genitourinary Cancer Disease Site Group. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations. Cancer Care Ontario Practice Guidelines Initiative 2008. <a href="http://www.cancercares.on.ca/pdf/pebc3-17s.pdf">http://www.cancercares.on.ca/pdf/pebc3-17s.pdf</a>	Radiotherapy and Androgen Deprivation In Combination After Local Surgery RADICALS ISRCTN40814031	Timing of intervention; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What is the best approach to treating the psychological impact of sexual dysfunction arising from prostate cancer treatment?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Environmental	Diet	Drug	Physical therapies	Vaccines and biologicals			Prostate Cancer: A JLA Priority Setting Partnership	Miles C, Candy B, Jones L, Williams R, Tookman A, King M. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005540. DOI: 10.1002/14651858.CD005540.pub2.	A pilot study of an intimacy-enhancing couples therapy for men with advanced prostate cancer and their partners <a href="http://clinicaltrials.gov/show/NCT00483678">http://clinicaltrials.gov/show/NCT00483678</a>	Quality of life; sexual function	

What is the best intervention for early stage, moderate risk prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug		Physical therapies	Surgery	Vaccines and biologicals	Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the best psycho-social intervention for partners of men with prostate cancer?*	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Psychological therapy								Prostate Cancer: A JLA Priority Setting Partnership	Chambers SK, Pinnock C, Lepore SJ. A systematic review of psychosocial interventions for men with prostate cancer and their partners. <i>Patient Education and Counseling</i> 2011; 85(2): e75-e88			Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.?EXPEDIENT NCT01562522	Social care
What is the best treatment for advanced prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Drug	Diet		Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the best treatment for men with high risk localised prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Drug	Diet		Physical therapies	Vaccines and biologicals	Surgery	Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the best treatment for prostate cancer recurrence?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Exercise	Environmental	Drug	Diet		Physical therapies	Surgery	Vaccines and biologicals	Prostate Cancer: A JLA Priority Setting Partnership	Cuppone F, Bria E, Giannarelli D. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. <i>BMC Cancer</i> 2010; 10:675				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the best way of managing the adverse effects from radiotherapy given for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Drug	Diet		Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership				The efficacy of cranberry capsules in the prevention and management of acute radiation cystitis in men treated with radiation for prostate cancer <a href="http://www.anzctr.org.au/ACTRN12611000887976.aspx">http://www.anzctr.org.au/ACTRN12611000887976.aspx</a> Rehabilitation After Radiotherapy for Prostate Cancer RePCa <a href="http://clinicaltrials.gov/show/NCT01272648">http://clinicaltrials.gov/show/NCT01272648</a>	Control of adverse effects
What is the best way stop prostate cancer spreading?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Exercise	Environmental	Drug	Diet		Physical therapies	Surgery	Vaccines and biologicals	Prostate Cancer: A JLA Priority Setting Partnership			National Horizon Scanning Centre.?Denosumab (AMG162) for prevention of bone metastases in prostate cancer.?Birmingham: National Horizon Scanning Centre (NHSC).?Horizon Scanning Technology Briefing.?2008 <a href="http://www.hps.bham.ac.uk/publichealth/horizon/outputs/documents/2008/sept-dec/Denosumab_prevention_bonemets_prostatescancer-Nonconf_ntv.pdf">http://www.hps.bham.ac.uk/publichealth/horizon/outputs/documents/2008/sept-dec/Denosumab_prevention_bonemets_prostatescancer-Nonconf_ntv.pdf</a>	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What is the best way to manage end of life care for men with advanced prostate cancer?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Service delivery								Prostate Cancer: A JLA Priority Setting Partnership	Esper P, Hampton J N, Finn J, Smith D C, Regiani S, Pienta K J.?A new concept in cancer care: the supportive care program.?American Journal of Hospice and Palliative Care?1999;116(6):713-722			End of life care	
What is the best way to manage pain in advanced prostate cancer?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Adult	Service delivery								Prostate Cancer: A JLA Priority Setting Partnership	Smith J E, Richardson J, Hoffman C, Pilkington K.?Mindfulness-based stress reduction as supportive therapy in cancer care: systematic review.?.Journal of Advanced Nursing?2005;752(3):7315-327			Pain	
What is the best way to treat hormone independent prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Diet	Drug		Physical therapies	Vaccines and biologicals		Prostate Cancer: A JLA Priority Setting Partnership				The ProtecT trial - evaluating the effectiveness of treatment for clinically localised prostate cancer ProtecT ISRCTN20141297	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the best way to treat low risk prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Diet	Drug		Physical therapies	Vaccines and biologicals	Surgery	Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the best way to treat the social impacts of a diagnosis of prostate cancer and its treatment?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Environmental	Exercise	Diet	Drug		Education and training	Psychological therapy	Physical therapies	Prostate Cancer: A JLA Priority Setting Partnership			Campbell H S, Phaneuf M R, Deane K.?Cancer peer support programs: do they work??.Patient Education and Counseling?2004;75(1):73-15		Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost

What is the effectiveness of gene therapy for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Vaccines and biologicals						Prostate Cancer: A JLA Priority Setting Partnership			A clinical study of adenovirus mediated Reduced Expression in Immortalized Cells/DocKopt-3(REC/Dok-3) gene therapy for prostate cancer <a href="http://www.umin.ac.jp/cttr/nd/ex.htm">http://www.umin.ac.jp/cttr/nd/ex.htm</a> A Phase I gene therapy study of FP253/Fludarabine for prostate cancer (FP253-GDEPT) <a href="http://clinicaltrials.gov/show/NCT00629430">http://clinicaltrials.gov/show/NCT00629430</a>	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What is the effectiveness of intermittent hormone therapy (known as intermittent androgen suppression (IAS) or intermittent androgen deprivation (IAD)) for prostate cancer?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Drug						Prostate Cancer: A JLA Priority Setting Partnership	De Conti P, Atallah ?N, Arruda HO, Soares BGO, El Di RP, Wilt T.J. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005009. DOI: 10.1002/14651858.CD005009.pub2.	Hurtado-Coll A, Goldenberg S L, Gleave M E, Klotz L. ?Intermittent androgen suppression in prostate cancer: the Canadian experience?. Urology?2002;?60(3A Supplement 5):?92-56	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost		
What is the effectiveness of maximal androgen blockade (i.e. an anti-androgen tablet and LHRH analogues) in treatment for prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Drug						Prostate Cancer: A JLA Priority Setting Partnership	Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T.J. Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 1999, Issue 2. Art. No.: CD001526. DOI: 10.1002/14651858.CD001526		Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost		
What is the effectiveness of new treatments for prostate cancer such as High Intensity Focused Ultrasound and Cryotherapy?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Physical therapies						Prostate Cancer: A JLA Priority Setting Partnership	Shelley M, Wilt T.J., Coles B, Mason M, Cryotherapy for localised prostate cancer. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD005010. DOI: 10.1002/14651858.CD005010.pub2. W armuth M, Johansson T, Mads P. Systematic review of the efficacy and safety of high intensity focused ultrasound for the primary and salvage treatment of prostate cancer. European Urology. 2010; 58: 803?815	National Institute for Clinical Excellence.?High-intensity focused ultrasound for prostate cancer?.London: National Institute for Clinical Excellence (NICE)?2005;?2 urf; <a href="http://www.nice.org.uk/ipcat.aspx?c=80298">http://www.nice.org.uk/ipcat.aspx?c=80298</a>	High-intensity focused ultrasound in treating patients with localised prostate cancer <a href="http://clinicaltrials.gov/show/NCT01194648">http://clinicaltrials.gov/show/NCT01194648</a> Salvage Cryotherapy in Recurrent Prostate Cancer SCORE <a href="http://clinicaltrials.gov/show/NCT00824928">http://clinicaltrials.gov/show/NCT00824928</a> To evaluate efficacy and tolerability of deferred androgen deprivation therapy +, upfront CryoTherapy in men with localised radiation recurrent Prostate cancer (RRPC) CROR ISRCTN72677380	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What is the effectiveness of radiotherapy as a secondary treatment in prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Radiotherapy						Prostate Cancer: A JLA Priority Setting Partnership	Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD007234. DOI: 10.1002/14651858.CD007234.pub2.	Morgan S C, Waldron T, Eapen L, Mayhew L A, Winquist E, Lukka H. Genitourinary Cancer Disease Site Group. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations. Cancer Care Ontario Practice Guidelines Initiative 2008. <a href="http://www.cancercare.on.ca/pdf/pebc3-17s.pdf">http://www.cancercare.on.ca/pdf/pebc3-17s.pdf</a>	The ProtecT trial - evaluating the effectiveness of treatment for clinically localised prostate cancer ProtecT ISRCTN20141297	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What is the evidence that dietary changes reduce the likelihood of recurrence of prostate cancer after radical treatment?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diet						Prostate Cancer: A JLA Priority Setting Partnership	Ilie D, Forbes KM, Hassed C. (2011) Lycopene for the prevention of prostate cancer. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008007. DOI: 10.1002/14651858.CD008007.pub2 Dennert G, Zwaahlen M, Brinman M et al. (2011) Selenium for preventing cancer. Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD006195. DOI: 10.1002/14651858.CD006195.pub2	Van Patten CL, de Boer JG, Tomlinson G, ES. ?Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.?Journal of Urology?2008;?180(6):?2314-2323	Does Protein Restriction Inhibit Prostate Cancer Growth NCT01692587 ?Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance NCT01238172	Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What is the evidence that taking supplements reduces the likelihood of recurrence after radical treatment for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diet	Drug					Prostate Cancer: A JLA Priority Setting Partnership			Soy protein in preventing recurrent cancer in patients who have undergone surgery for Stage II prostate cancer <a href="http://clinicaltrials.gov/show/NCT00765479">http://clinicaltrials.gov/show/NCT00765479</a>	Time to recurrence	
What is the most effective form of ADT (androgen deprivation therapy) for prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Drug						Prostate Cancer: A JLA Priority Setting Partnership			Augustovski F, Colantonio L, Pichon Riviere A. ?Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer.?Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS)?2006	Androgen deprivation therapy in treating patients with prostate cancer <a href="http://clinicaltrials.gov/show/NCT00110162">http://clinicaltrials.gov/show/NCT00110162</a>	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What is the optimal time between follow up appointments for men who have been treated for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic						Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
What self-help actions can aid recovery from treatment for prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training						Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	

What tests should be used after a positive biopsy result to assess spread outside the prostate capsule?	Uncertainties identified from clinicians' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Illic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2.			Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
What would be the best way to deal with comorbid illnesses for people with prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Exercise	Environmental	Diet	Drug	Physical therapies	Vaccines and biologicals	Surgery	Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Which hormone therapy, continuous or intermittent, is more effective in treating prostate cancer?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership		Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Rockville, MD, USA: Agency for Health Care Policy and Research. Evidence Report/Technology Assessment: 4.71999 <a href="http://www.aahrq.gov/clinic/epcsums/prosumm.htm">http://www.aahrq.gov/clinic/epcsums/prosumm.htm</a>	Time to progression of disease; mortality; Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost	
Will staging of prostate cancer patients be better using MRI Scans and will this improve treatment outcomes?	Uncertainties identified from patients' questions	Existing relevant systematic reviews are not up-to-date	Adult	Devices							Prostate Cancer: A JLA Priority Setting Partnership			Hailey D. Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 72003 <a href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;ID=32003001149">http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;ID=32003001149</a>	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would a screening programme for prostate cancer for men age 50 or above benefit outcomes?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Illic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2. Chou R, Crowell JM et al. (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Annals of Internal Medicine 155: 762-771 Lumen N, Fonteyne V, De Meerleert G, et al. (2012) Population screening for prostate cancer: an overview of available studies and meta-analysis. International Journal of Urology 19: 100-108 Shen PF, Zhu YC, Wei WR et al. (2012) The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian Journal of Andrology 14: 310-315 Djubergovic M, Beyth RJ, Neuberger et al. (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543		Diagnosis	
Would a screening programme for prostate cancer for men younger than 50 benefit outcomes?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership	Illic D, O'Connor D, Green S, Wilt T.J. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub2 Lumen N, Fonteyne V, De Meerleert G et al. (2012) Population screening for prostate cancer: an overview of available studies and meta-analysis. International Journal of Urology 19: 100-108 Djubergovic M, Beyth RJ, Neuberger MM et al. (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543		Diagnosis	
Would a 'whole life' scoring tool predict the risk of developing prostate cancer and would using it allow me to make choices that would reduce my risk of developing prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Incidence of prostate cancer; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would an awareness programme targeted at African/Caribbean men improve outcomes for men of this ethnic group?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership				Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would delivery of radiotherapy in fewer and larger doses (hypofractionation) improve prostate cancer outcomes?	Uncertainties identified from clinicians' questions	Existing relevant systematic reviews are not up-to-date	Adult	Radiotherapy							Prostate Cancer: A JLA Priority Setting Partnership		Hummel S, Simpson E, Hemingway P, Stevenson M, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment 2010 14(47) 1-108. <a href="http://www.hta.ac.uk/execcsum/summ1447.htm">http://www.hta.ac.uk/execcsum/summ1447.htm</a>	Phase 2 hypofractionation study using proton beam therapy for prostate adenocarcinoma NCT01709253 A feasibility trial of proton radiation therapy or intensity modulated radiation therapy (IMRT) using mild hypofractionation for intermediate-risk adenocarcinoma of the prostate. NCT01352429 ISRCTN46906321	Symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost

Would dietary control of animal fats, and particularly dairy products, help reduce my risk of, or provide a protective effect against my prostate cancer getting worse?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diet							Prostate Cancer: A JLA Priority Setting Partnership					Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would earlier chemotherapy improve the outcomes of treatment for prostate cancer patients?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership	Mhaskar AR, Quinn G, Vadaparampil S, Djulbegovic S, Gwede CK, Kumar A. Timing of first-line cancer treatments - early versus late: a systematic review of phase III randomized trials. <i>Cancer Treatment Reviews</i> 2010; 36(8): 621-8 PMID 20444550				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would improving surgical techniques help improve outcomes for patients with prostate cancer?	Uncertainties identified from patients' questions	Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects	Adult	Surgery							Prostate Cancer: A JLA Priority Setting Partnership	Surgical robotics in urology <a href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;ID=32007000772">http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;ID=32007000772</a> Health Information and Quality Authority. Health technology assessment of robot-assisted surgery in selected surgical procedures. 2011 <a href="http://www.hiqa.ie/system/files/HTA-robot-assisted-surgery.pdf">www.hiqa.ie/system/files/HTA-robot-assisted-surgery.pdf</a>				Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would introducing new treatments early on improve outcomes for people with prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Environmental	Exercise	Diet	Drug	Physical therapies	Surgery	Vaccines and biologicals	Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would knowing about other early symptoms of prostate cancer, other than urinary symptoms, improve the outcomes of treatment?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would prostate cancer screening targeted at high risk groups, i.e. those with positive family history, and ethnic minorities with higher rates, improve the outcomes of treatment in these groups?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Adult	Service delivery							Prostate Cancer: A JLA Priority Setting Partnership				Family History in Prostate Cancer Patients in Taiwan NCT00155025	Incidence; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would restoration of testosterone levels prevent or delay onset of hormone independent prostate cancer?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Drug							Prostate Cancer: A JLA Priority Setting Partnership					Symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would screening of men with a female family history of breast and/or ovarian cancer reduce their risk of being wrongly diagnosed with prostate cancer, and over- or under-treated?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				A study looking at screening for men who are at an increased risk of developing prostate cancer (IMPACT) <a href="http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-at-screening-for-men-who-are-at-an-increased-risk-of-developing-prostate-cancer">http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-at-screening-for-men-who-are-at-an-increased-risk-of-developing-prostate-cancer</a>	Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would screening the family members of patients who have cancer identify those who go on to develop prostate cancer?	Uncertainties identified from carers' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership				Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives NCT01013129 Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom NCT00758173 Gene-Environment Interaction in Prostate Cancer NCT00041847 A study looking at screening for men who are at an increased risk of developing prostate cancer (IMPACT) <a href="http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-at-screening-for-men-who-are-at-an-increased-risk-of-developing-prostate-cancer">http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-at-screening-for-men-who-are-at-an-increased-risk-of-developing-prostate-cancer</a>	Incidence of prostate cancer; symptom control; symptom management; disease progression, time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would targeted screening in specific occupations and residential groups reduce prostate cancer risk?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Diagnostic							Prostate Cancer: A JLA Priority Setting Partnership					Incidence of prostate cancer

Would the introduction of targeted screening for men with a family history of prostate cancer help with early diagnosis and improve outcomes?	Uncertainties identified from clinicians' questions	No relevant systematic reviews identified	Adult	Service delivery						Prostate Cancer: A JLA Priority Setting Partnership				Family History in Prostate Cancer Patients in Taiwan NCT00155025	Incidence; symptom control; symptom management; disease progression; time to disease progression; adverse effects or complications; acceptability to patient, and cost
Would training support staff on issues such as state benefits improve the uptake of the same for men and their partners with prostate cancer?	Uncertainties identified from patients' questions	No relevant systematic reviews identified	Adult	Education and training						Prostate Cancer: A JLA Priority Setting Partnership					Social care